Regulatory T cells and treatment of cancer - PubMed (original) (raw)

Review

Regulatory T cells and treatment of cancer

Tyler J Curiel. Curr Opin Immunol. 2008 Apr.

Abstract

CD4+CD25+FOXP3+ regulatory T cells (Tregs) are elevated in cancers and can thwart protective antitumor immunity. Recent human cancer trials suggest that depleting Tregs can be clinically beneficial. Additional types of deleterious regulatory cells are also increased in cancer. Tregs also play unanticipated roles in cancer therapy in that some drugs unexpectedly increase (e.g. cancer vaccines or IL-2 treatment) or decrease (e.g. antineoangiogenesis agents or receptor tyrosine kinase inhibitors) their numbers or function. Managing deleterious effects of regulatory cells represents a novel and potentially effective way to give immunotherapy for cancer. New insights into molecular mechanisms governing trafficking, differentiation, and function of these cells suggest novel approaches to manipulating them as treatment strategies.

PubMed Disclaimer

References

1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307. - PubMed
2. This is a comprehensive review of the subject.
1. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–1174. - PMC - PubMed
2. This paper examines how infectious disease models shaped tumor immunotherapy, perhaps not always for the better.
1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–274. - PubMed
1. Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W, Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: A novel means to boost efficacy. Frontiers in Bioscience. 2007 in press. - PubMed
1. Curiel TJ. Regulatory T-cell development: is Foxp3 the decider? Nat Med. 2007;13:250–253. - PubMed

Regulatory T cells and treatment of cancer - PubMed (original) (raw)